- Volume 14 Issue 6
DOI QR Code
Secondline Chemotherapy Versus Best Supportive Care in Patient with Malignant Pleural Mesothelioma: A Retrospective Study
- Mutlu, Hasan (Department of Medical Oncology, Acibadem Kayseri Hospital) ;
- Buyukcelik, Abdullah (Department of Internal Medicine, Acibadem University School of Medicine) ;
- Karaca, Halit (Department of Medical Oncology, Erciyes University School of Medicine) ;
- Aksahin, Arzu (Department of Medical Oncology, Kayseri Research and Training Hospital) ;
- Berk, Veli (Department of Medical Oncology, Erciyes University School of Medicine) ;
- Aslan, Tuncay (Department of Internal Medicine, Kayseri Research and Training Hospital) ;
- Erden, Abdulsamet (Department of Internal Medicine, Kayseri Research and Training Hospital) ;
- Akca, Zeki (Department of Radiation Oncology, Mersin Goverment Hospital) ;
- Ozkan, Metin (Department of Medical Oncology, Erciyes University School of Medicine)
- Published : 2013.06.30
Introduction: Mesothelioma is a rare neoplasm arising from mesothelial surfaces with the malignant pleural mesothelioma (MPM) as the most common form. Secondline chemotherapy in MPM is still controversial and in this study we evaluated whether it is superior to best supportive care. Materials and Methods: A total of 51 patients with MPM from Acibadem Kayseri Hospital, Kayseri Training and Research Hospital and Erciyes University were analyzed retrospectively. The patients treated with secondline chemotherapies (SLCT) were compared with those treated with best supportive care (BSC) for overall survival. Results: The median overall survival (OS) for firstline chemotherapy
- Agatsuma T, Koizumi T, Yasuo M, et al (2010). Successful salvage chemotherapy with gemcitabine and vinorelbine in a malignant pleuralmesothelioma patient previously treated with pemetrexed. Jpn J Clin Oncol, 40, 1180-3. https://doi.org/10.1093/jjco/hyq101
- Bott M, Brevet M, Taylor BS, et al (2011). The nuclear deubiquitinase BAP1 is commonly inactivated by somatic mutations and 3p21.1 losses in malignant pleural mesothelioma. Nat Genet, 43, 668-72 https://doi.org/10.1038/ng.855
- Ceresoli GL, Zucali PA, Gianoncelli L, Lorenzi E, Santoro A (2010). Second-line treatment for malignant pleural mesothelioma. Cancer Treat Rev, 36, 24-32 https://doi.org/10.1016/j.ctrv.2009.09.003
- Curran D, Sahmoud T, Therasse P, et al (1998). Prognostic factors in patients with pleural mesothelioma: the European organization for research and treatment of cancer experience. J Clin Oncol, 16, 145-52.
- Edwards JG, Abrams KR, Leverment JN, et al (2000). Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems. Thorax, 55, 731-5. https://doi.org/10.1136/thorax.55.9.731
- Gulmez I, Kart L, Buyukoglan H, et al (2004). Evaluation of malignant mesothelioma in central Anatolia: a study of 67 cases. Can Respir J, 11, 287-90.
- Jassem J, Ramlau R, Santoro A, et al (2008). Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol, 26, 1698-704. https://doi.org/10.1200/JCO.2006.09.9887
- Manegold C, Symanowski J, Gatzemeier U, et al (2005). Secondline (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma. Ann Oncol, 16, 923-7.
- Margery J, Riviere F, Planchard D, et al (2010). Second-line therapy in patients with malignant pleural mesothelioma. A French retrospective study (2005-2006). Rev Pneumol Clin, 66, 255-9. https://doi.org/10.1016/j.pneumo.2010.07.013
- Pasello G, Nicotra S, Marulli G, et al (2011). Platinum-based doublet chemotherapy in pre-treated malignant pleural mesothelioma (MPM) patients: a mono-institutional experience. Lung Cancer, 73, 351-5. https://doi.org/10.1016/j.lungcan.2011.01.005
- Pass HI, Vogelzang NJ, Hahn SH, Carbone M (2011). Benign and malignant mesothelioma, in: DeVita VT, Lawrence TS, Rosenberg SA (Eds): cancer principles and practice of oncology 9th edition. Lippicott Williams & Wilkins USA, 138, 2052-62.
- Remon J, Lianes P, Martinez S, et al (2012). Malignant mesothelioma: new insights into a rare disease. Cancer Treat Rev, [Epub ahead of print].
- Sorensen JB, Sundstrom S, Perell K, Thielsen AK (2007). Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment. J Thorac Oncol, 2, 147-52.
- Tourkantonis I, Makrilia N, Ralli M, et al (2011). Phase II study of gemcitabine plus docetaxel as second-line treatment in malignant pleuralmesothelioma: a single institution study. Am J Clin Oncol, 34, 38-42. https://doi.org/10.1097/COC.0b013e3181cae90e
- van Meerbeeck JP, Gaafar R, Manegold C, et al (2005). European organisation for research and treatment of cancer lung cancer group; national cancer institute of Canada. Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European organisation for research and treatment of cancer lung cancer group and the national cancer institute of Canada. J Clin Oncol, 23, 6881-8 https://doi.org/10.1200/JCO.20005.14.589
- Vogelzang NJ, Rusthoven JJ, Symanowski J, et al (2003). Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol, 21, 2636-44. https://doi.org/10.1200/JCO.2003.11.136
- Second-line gemcitabine-based chemotherapy regimens improve overall 3-year survival rate in patients with malignant pleural mesothelioma: a multicenter retrospective study vol.31, pp.8, 2014, https://doi.org/10.1007/s12032-014-0074-9
- Symptom burden in mesothelioma patients admitted to home palliative care vol.32, pp.12, 2016, https://doi.org/10.1080/03007995.2016.1226165